SO-31 ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer
Title:
SO-31 ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer
Author:
Chung, H. Lee, K. Kim, W. Gainor, J. Lakhani, N. Chow, L. Messersmith, W. Fanning, P. Squifflet, P. Jin, F. Forgie, A. Wan, H. Pons, J. Randolph, S. LoRusso, P.